Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 5.78B P/E - EPS this Y -42.20% Ern Qtrly Grth -
Income -365.74M Forward P/E -12.03 EPS next Y 1.60% 50D Avg Chg -2.00%
Sales 813.46M PEG -0.32 EPS past 5Y - 200D Avg Chg 3.00%
Dividend N/A Price/Book 11.88 EPS next 5Y 35.30% 52W High Chg -17.00%
Recommedations 2.00 Quick Ratio 6.90 Shares Outstanding 157.71M 52W Low Chg 24.00%
Insider Own 0.78% ROA -7.58% Shares Float 145.05M Beta 0.39
Inst Own 95.64% ROE -105.71% Shares Shorted/Prior 10.61M/9.90M Price 40.41
Gross Margin -12.86% Profit Margin -44.96% Avg. Volume 1,297,700 Target Price 62.13
Oper. Margin -29.34% Earnings Date Oct 31 Volume 711,644 Change -1.94%
About Ionis Pharmaceuticals, Inc.

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.

Ionis Pharmaceuticals, Inc. News
12/23/24 Are Investors Undervaluing Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) By 30%?
12/20/24 FDA approves Ionis’ TRYNGOLZA for FCS treatment
12/20/24 Ionis Gets FDA Approval for Rare Disease Drug Tryngolza
12/20/24 FDA Approves Ionis Pharmaceuticals' Rare Genetic Disease Therapy to Lower High-Level Of Fat In Blood
12/19/24 TRYNGOLZA™ (olezarsen) approved in U.S. as first-ever treatment for adults living with familial chylomicronemia syndrome as an adjunct to diet
12/12/24 Theravance Bio (TBPH) Up 3.7% Since Last Earnings Report: Can It Continue?
12/11/24 How Much Upside is Left in Ionis Pharmaceuticals (IONS)? Wall Street Analysts Think 55.91%
12/06/24 Ionis Pharmaceuticals (IONS) Down 4.5% Since Last Earnings Report: Can It Rebound?
12/05/24 Theratechnologies enters exclusive licensing agreement with Ionis
11/27/24 Ionis Pharmaceuticals (IONS) Upgraded to Buy: What Does It Mean for the Stock?
11/21/24 Why Is Ionis Pharmaceuticals, Inc. (IONS) Among the Worst Performing Biotech Stocks in 2024?
11/19/24 Ionis Pharmaceuticals, Inc. (IONS): Among the Best Genomics Stocks to Buy Right Now
11/18/24 Here's Why Ionis Pharmaceuticals (IONS) is Poised for a Turnaround After Losing -13.46% in 4 Weeks
11/08/24 Ionis Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations
11/07/24 Ionis' Q3 Earnings and Revenues Beat Estimates, New Launches in Focus
11/07/24 Company News for Nov 7, 2024
11/07/24 Ionis to present at upcoming investor conferences
11/07/24 Ionis announces design for Phase III trial of Angelman syndrome therapy
11/07/24 Q3 2024 Ionis Pharmaceuticals Inc Earnings Call
11/07/24 Ionis Pharmaceuticals Inc (IONS) Q3 2024 Earnings Call Highlights: Navigating Revenue ...
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Swayze Eric EVP Research EVP Research Jan 31 Sell 50.78 12,680 643,890 34,324 02/02/24
Schneider Eugene EVP, Chf Clinical De.. EVP, Chf Clinical Develop Ofcr Feb 01 Sell 49.59 2,071 102,701 49,812 02/02/24
O'NEIL PATRICK R. EVP CLO & General Co.. EVP CLO & General Counsel Feb 01 Sell 49.67 1,961 97,403 48,661 02/02/24
Monia Brett P Chief Executive Offi.. Chief Executive Officer Feb 01 Sell 49.37 23,501 1,160,244 174,138 02/02/24
HOUGEN ELIZABETH L EVP, Finance & CFO EVP, Finance & CFO Feb 01 Sell 49.54 2,125 105,272 92,905 02/02/24
Geary Richard S EVP, Chief Developme.. EVP, Chief Development Officer Feb 01 Sell 50.04 1,961 98,128 87,334 02/02/24
Cadoret-Manier Onaiza EVP, Chf GL Pdt Str.. EVP, Chf GL Pdt Str & Oper Ofc Feb 01 Sell 49.6 2,125 105,400 35,825 02/02/24
BENNETT C FRANK EVP, Chief Scientifi.. EVP, Chief Scientific Officer Feb 01 Sell 49.52 1,853 91,761 79,079 02/02/24
Monia Brett P Chief Executive Offi.. Chief Executive Officer Jan 25 Sell 51.75 2,285 118,249 151,851 01/29/24
O'NEIL PATRICK R. EVP CLO & General Co.. EVP CLO & General Counsel Jan 25 Sell 51.75 6,450 333,788 46,802 01/29/24
Cadoret-Manier Onaiza EVP, Chf GL Pdt Str.. EVP, Chf GL Pdt Str & Oper Ofc Jan 16 Sell 50.42 5,564 280,537 33,810 01/18/24
Cadoret-Manier Onaiza EVP, Chf GL Pdt Str.. EVP, Chf GL Pdt Str & Oper Ofc Jan 16 Option 0 15,062 39,374 01/18/24
O'NEIL PATRICK R. EVP CLO & General Co.. EVP CLO & General Counsel Jan 16 Sell 50.42 7,744 390,452 53,252 01/18/24
O'NEIL PATRICK R. EVP CLO & General Co.. EVP CLO & General Counsel Jan 16 Option 0 20,641 60,996 01/18/24
Birchler Brian EVP, Corp and Develo.. EVP, Corp and Development Ops Jan 16 Sell 50.42 4,497 226,739 44,582 01/18/24
Birchler Brian EVP, Corp and Develo.. EVP, Corp and Development Ops Jan 16 Option 0 12,080 49,079 01/18/24
Swayze Eric EVP Research EVP Research Jan 16 Sell 50.42 6,305 317,898 85 01/18/24
Swayze Eric EVP Research EVP Research Jan 16 Option 0 17,090 94 01/18/24
Schneider Eugene EVP, Chf Clinical De.. EVP, Chf Clinical Develop Ofcr Jan 16 Sell 50.42 5,482 276,402 47,850 01/18/24
Schneider Eugene EVP, Chf Clinical De.. EVP, Chf Clinical Develop Ofcr Jan 16 Option 0 15,162 53,332 01/18/24
Monia Brett P Chief Executive Offi.. Chief Executive Officer Jan 16 Sell 50.42 32,059 1,616,415 154,136 01/18/24
Monia Brett P Chief Executive Offi.. Chief Executive Officer Jan 16 Option 0 68,084 186,195 01/18/24
Schneider Eugene EVP, Chf Clinical De.. EVP, Chf Clinical Develop Ofcr Jan 12 Sell 53.5 8,000 428,000 38,170 01/17/24
Schneider Eugene EVP, Chf Clinical De.. EVP, Chf Clinical Develop Ofcr Jan 12 Option 32.6 8,000 260,800 46,170 01/17/24
Swayze Eric EVP Research EVP Research Dec 28 Option 47.34 27,100 1,282,914 59,616 01/02/24
Swayze Eric EVP Research EVP Research Dec 28 Sell 50.19 27,100 1,360,149 32,516 01/02/24
HOUGEN ELIZABETH L EVP, Finance & CFO EVP, Finance & CFO Dec 28 Option 47.34 45,225 2,140,952 120,884 01/02/24
Birchler Brian EVP, Corp and Develo.. EVP, Corp and Development Ops Dec 28 Option 47.34 11,500 544,410 48,028 01/02/24
O'NEIL PATRICK R. EVP CLO & General Co.. EVP CLO & General Counsel Dec 26 Sell 51.46 20,825 1,071,654 40,355 12/28/23
O'NEIL PATRICK R. EVP CLO & General Co.. EVP CLO & General Counsel Dec 26 Option 47.34 20,825 985,856 61,180 12/28/23
PARSHALL B LYNNE Director Director Dec 26 Sell 50.63 117,638 5,956,012 82,588 12/28/23
PARSHALL B LYNNE Director Director Dec 26 Option 47.34 117,638 5,568,983 125,113 12/28/23
Schneider Eugene EVP, Chf Clinical De.. EVP, Chf Clinical Develop Ofcr Dec 26 Sell 51.46 25,000 1,286,500 36,052 12/28/23
Schneider Eugene EVP, Chf Clinical De.. EVP, Chf Clinical Develop Ofcr Dec 26 Option 47.34 25,000 1,183,500 61,052 12/28/23
BENNETT C FRANK EVP, Chief Scientifi.. EVP, Chief Scientific Officer Dec 20 Sell 49.46 22,613 1,118,439 65,754 12/22/23
BENNETT C FRANK EVP, Chief Scientifi.. EVP, Chief Scientific Officer Dec 20 Option 47.34 22,613 1,070,499 81,867 12/22/23
Geary Richard S EVP, Chief Developme.. EVP, Chief Development Officer Dec 20 Option 47.34 10,612 502,372 77,073 12/22/23
Geary Richard S EVP, Chief Developme.. EVP, Chief Development Officer Dec 20 Sell 49.46 10,612 524,870 72,961 12/22/23
Monia Brett P Chief Executive Offi.. Chief Executive Officer Dec 20 Sell 49.46 24,000 1,187,040 118,111 12/22/23
Monia Brett P Chief Executive Offi.. Chief Executive Officer Dec 20 Option 47.34 24,000 1,136,160 135,611 12/22/23
Swayze Eric EVP Research EVP Research Oct 16 Sell 47.95 52 2,493 73 10/18/23
Swayze Eric EVP Research EVP Research Oct 16 Option 0 125 125 10/18/23
BENNETT C FRANK EVP, Chief Scientifi.. EVP, Chief Scientific Officer Sep 28 Sell 46.5 4,460 207,390 65,754 09/29/23
PARSHALL B LYNNE Director Director Sep 26 Sell 45.1268 10,000 451,268 82,588 09/28/23
KLEIN JOSEPH III Director Director Sep 26 Sell 45.1268 2,000 90,254 18,346 09/28/23
Diaz Allene M. Director Director Aug 01 Sell 41.05 657 26,970 12,676 08/03/23
KLEIN JOSEPH III Director Director Jul 17 Sell 42 3,555 149,310 20,346 07/19/23
KLEIN JOSEPH III Director Director Jul 17 Option 0 7,110 23,901 07/19/23
Diaz Allene M. Director Director Jul 17 Option 0.0 5,333 13,333 07/19/23
Monia Brett P Chief Executive Offi.. Chief Executive Officer Jul 07 Sell 42.2495 18,650 787,953 121,724 07/11/23